Weekly standard doses of rh-EPO are highly effective for the treatment of anemic patients with low-intermediate 1 risk myelodysplastic syndromes

Leukemia Research

Volumn 35, Issue 11, 2011, Pages 1472-1476

  Balleari, Enrico ^a,b   Clavio, Marino ^a,b   Arboscello, Eleonora ^a,b   Bellodi, Andrea ^a,b   Bruzzone, Andrea ^a,b   Del Corso, Lisette ^a,b   Lucchetti, Maria Vita ^a,b   Miglino, Maurizio ^a,b   Passalia, Caterina ^a,b   Pierri, Ivana ^a,b   Ponassi, Irene ^a,b   Oneto, Caterina ^a,b   Racchi, Omar ^a,b   Scudeletti, Marco ^c   Vignolo, Luana ^a,b   Zoppoli, Gabriele ^a,b   Gobbi, Marco ^a,b   Ghio, Riccardo ^a,b  

^a UNIVERSITY OF GENOA   (Italy)

^b UNIVERSITY OF GENOA   (Italy)

^c ASL 4   (Italy)

Author keywords

Anemia; Erythropoietic stimulating agents; Erythropoietin; IPSS; Low risk myelodysplastic syndromes; WPSS

Indexed keywords

RECOMBINANT ERYTHROPOIETIN;

ADULT; AGED; ARTICLE; CANCER RISK; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; HUMAN; INFORMED CONSENT; INJECTION SITE PRURITUS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; REFRACTORY ANEMIA; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANEMIA; DOSE-RESPONSE RELATIONSHIP, DRUG; ERYTHROPOIETIN; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; PROGNOSIS; RECOMBINANT PROTEINS; RISK FACTORS;

EID: 80053976546     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2011.05.025     Document Type: Article

References (26)

1. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2088.
2. Heaney M.L., Golde D.W. Myelodysplasia. N Engl J Med 1999, 340:1649-1660.
3. Hellstrom-Lindberg E. Efficacy of erythropoietin in the myelodysplastic syndromes: a meta-analysis of 205 patients from 17 studies. Br J Haematol 1995, 89:67-71.
4. Ross S.D., Allen I.E., Probst C.A., et al. Efficacy and safety of erythropoiesis-stimulating proteins in myelodyspslatic syndromes: a systematic review and meta-analysis. Oncologist 2007, 12:1264-1273.
5. Spiriti M.A., Latagliata R., Niscola P., et al. Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome. Ann Hematol 2005, 84:167-176.
6. Latagliata R., Oliva E.N., Volpicelli P., et al. Twice-weekly high-dose rHuEpo for the treatment of anemia in patients with low-risk myelodysplastic syndromes. Acta Haematol 2008, 120:104-107.
7. Gabrilove J., Pasquette R., Lyons R.M., et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoietin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol 2008, 142:379-393.
8. Santini V., Alessandrino P.E., Angelucci E., et al. Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. Leuk Res 2010, 34:1576-1588.
9. Jädersten M., Montgomery S.M., Dybedal I., et al. Long-term outcome of treatment of anemia in MDS with erythropoietin and G-CSF. Blood 2005, 106:803-811.
10. Swerdlow S.H., Campo E., Harris N.L., et al. World Health Organization classification of tumours of the hematopoietic and lymphoid tissues 2008, WHO Press.
11. Cheson B.D., Greenberg P.L., Bennett J.M., et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood 2006, 108:419-425.
12. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 10(25):3503-3510.
13. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects on quality of life. Br J Haematol 2003, 120:1037-1046.
14. Terpos E., Mougiou A., Kouraklis A., For The Greek MDS Study Group, et al. Prolonged administration of erythropoietin increases erythroid response rate in myelodysplastic syndromes: a phase II trial in 281 patients. Br J Haematol 2002, 118:174-180.
15. Musto P., Falcone A., Sanpaolo G., et al. Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes. Br J Haematol 2003, 122:269-271.
16. Stasi R., Brunetti M., Terzoli E., et al. Once-weekly dosing of recombinant human erythropoietin alpha in patients with myelodysplastic syndromes unresponsive to conventional dosing. Ann Oncol 2004, 15:1684-1690.
17. Hellstrom-Lindberg E., Ahlgren T., Beguin Y., et al. Treatment of the anemia in myelodysplastic syndromes with granulocyte colony-stimulating factor plus erythropoietin: results from a randomised phase II study and long term follow-up of 71 patients. Blood 1998, 92:68-75.
18. Mundle S., Lefebvre P., Vekeman F., et al. An assessment of erythroid response to epoetin alpha as a single agent versus in combination with granulocyte- or granulocyte-macrophage-colony-stimulating factor in myelodysplastic syndromes using a meta-analysis approach. Cancer 2009, 115:706-715.
19. Moyo V., Lefebvre P., Duh M.S., et al. Erythropoiesis-stimulating agents in the treatment of anemia in myelodysplastic syndromes: a meta-analysis. Ann Hematol 2008, 87:527-536.
20. A randomised, double blind, placebo controlled study with subcutaneous human erythropoietin in patients with low risk myelodysplastic syndromes. Br J Haematol 1998, 103:1070-1074. Italian Cooperative Study Group for rHuEpo in myelodysplastic syndromes.
21. Di Raimondo F., Longo G., Cacciola E., et al. A good response rate to recombinant erythropoietin alone may be expected in selected myelodysplastic patients. A preliminary clinical study. Eur J Haematol 1996, 56:7-11.
22. Balleari E., Rossi E., Clavio M., et al. Erythropoietin plus granulocyte colony-stimulating factor is better than erythropoietin alone to treat anemia in low-risk myelodysplastic syndromes: results from a randomized single-centre study. Ann Hematol 2006, 85:174-180.
23. Kim D.Y., Lee J.H., Lee J.H., et al. Comparison of various criteria in predicting treatment response and prognosis of patients with myelodysplastic syndrome treated with azacitidine. Ann Hematol 2010, 89:15-23.
24. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
25. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613. JCO 2008.
26. Musto P., Villani O., Martorelli M.C., et al. Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. Leuk Res 2010, 34:981-985.